Summary by Futu AI
Exicure, Inc., a biotechnology company listed on NASDAQ under the ticker XCUR, has been involved in a significant transaction according to a Schedule 13D/A filing with the U.S. Securities and Exchange Commission. The amendment, filed on March 4, 2024, details the actions of two major shareholders, CBI USA, Inc. and DGP Co., Ltd., both of which have reported substantial ownership stakes in Exicure. As of February 29, 2024, DGP Co., Ltd. holds 35.4% of Exicure's outstanding common stock, while CBI USA, Inc. owns 9.5%. Collectively, they control 44.8% of the company's shares. The filing reveals that DGP Co., Ltd. entered into a stock purchase agreement with OverdigmK Co., Ltd., a company based in the Republic of Korea, to sell 3,400,000 shares of Exicure for 6 billion...Show More